| English |
| busulfan |
  |
|
| Attestation |
3
|
| Part of speech |
Noun
|
| Grammatical label |
Uncountable
|
| Definition |
Busulfan is a bifunctional alkylating agent known chemically as 1,4-butanediol, dimethanesulfonate. It is a potent cytotoxic drug that causes profound myelosuppression at the recommended dosage. It is a fundamental part of myeloablative regimens used for patients undergoing bone marrow transplantation for malignant and non-malignant conditions (thalassemias). High-dose busulfan in combination with cyclophosphamide is particularly attractive in children, as significant total body irradiation-related mortality and morbidity, especially involving the developing central nervous system, endocrine system and skeletal system, can be avoided.
|
| Definition source |
Pawlowska, AB., et al. (1997). ‘Relationship of plasma pharmacokinetics of high-dose busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia’. Bone Marrow Transplantation 20(11):915-920. (RISCEN129)
|
| Context |
Busulfan is fat soluble and readily crosses the blood-brain barrier to the site of MS plaques. Busulfan is administered orally with variability in absorption and first-pass hepatic metabolism.
|
| Context source |
Richard K.,et al. (2002). ‘Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?’. Blood 99(3): 768-784. (RISCEN68)
|
| Subject field |
Haemopoiesis
|
| Sub-field (level 1) |
Thalassemias
|
| Sub-field (level 2) |
Therapies
|
| Generic concept |
Immunosuppressing agent, alkylating agent
|
| Coordinate concept |
Cyclosporine, cyclophosphamide, metotrexate, antilymphocyte globulin
|
| Related concept |
Marrow cavity, eradication, conditioning regimen
|
| it |
Busulfano
|
| Reliability code |
3
|
